What hematopathology tells us about the future of pathology informatics

Archives of Pathology and Laboratory Medicine

Volumn 133, Issue 6, 2009, Pages 908-911

  Hess, Jay L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BREAKPOINT CLUSTER REGION PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; BONE MARROW BIOPSY; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DEMOGRAPHY; FLOW CYTOMETRY; HUMAN; INFORMATION SCIENCE; MICROARRAY ANALYSIS; POLYMERASE CHAIN REACTION; REVIEW;

HEMATOLOGY; HUMANS; MEDICAL INFORMATICS; PATHOLOGY, CLINICAL;

EID: 67049108794     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Nowell PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science. 1960;132:1497.
2. Bartram CR, de Klein A, Hagemeijer A, et al. Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia. Nature. 1983;306:277-280. (Pubitemid 14232360)
3. Koretzky GA. The legacy of the Philadelphia chromosome. J Clin Invest. 2007;117:2030-2032. (Pubitemid 47219541)
4. Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia [comment in: N Engl J Med. 2003;349:1399-1401]. N Engl J Med. 2003;349:1423-1432.
5. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417. (Pubitemid 44903745)
6. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Eng J Med. 2006;354:2531-2541. (Pubitemid 43882349)
7. Mrozek K, Heerema NA, Bloomfield CD. Cytogenetics in acute leukemia. Blood Rev. 2004;18:115-136. (Pubitemid 38380667)
8. Pui CH, Evans WE. Acute lymphoblastic leukemia. N Engl J Med. 1998;339:605-615. (Pubitemid 28385659)
9. Percy MJ, McMullin MF. The V617F JAK2 mutation and the myeloproliferative disorders. Hematol Oncol. 2005;23:91-93. (Pubitemid 43061885)
10. World Health Organization. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Vol 1. 1st ed. Lyon, France: IARC Press; 2001.
11. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511. (Pubitemid 30082188)
12. Houde C, Li Y, Song L, et al. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood. 2004;104:3697-3704. (Pubitemid 39564447)
13. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435:834-838. (Pubitemid 40839735)
14. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature. 2007;446:758-764. (Pubitemid 46582031)
15. Wadelius M, Chen LY, Eriksson N, et al. Association of warfarin dose with genes involved in its action and metabolism. Hum Genetics. 2007;121:23-34. (Pubitemid 46421137)
16. Cheok MH, Evans WE. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy [erratum in: Nat Rev Cancer. 2006;6:249]. Nature Rev Cancer. 2006;6:117-129.
17. Tyner J, Walters D, Willis S, et al. RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia. Blood. 2008;111:2238-2245.
18. Sinard JH, Morrow JS. Informatics and anatomic pathology: meeting challenges and charting the future. Hum Pathol. 2001;32:143-148. (Pubitemid 32193711)